JNJ-38877605 is primarily used in cancer research due to its role as a selective inhibitor of the c-Met receptor tyrosine kinase. This receptor is often overexpressed or mutated in various types of cancers, including lung, liver, and gastric cancers, making it a key target for therapeutic intervention. By inhibiting c-Met, JNJ-38877605 helps to disrupt signaling pathways that promote tumor growth, invasion, and metastasis. It is commonly employed in preclinical studies to evaluate its efficacy in reducing tumor progression and enhancing the effectiveness of other cancer treatments. Additionally, it serves as a valuable tool for understanding the molecular mechanisms of c-Met-driven oncogenesis and for developing novel targeted therapies.